INDIAN pharmaceutical company MSN Laboratories has established a wholly owned subsidiary in Jamaica, positioning the country as a strategic hub for its expansion into the Caribbean generics market amid growing regional demand for affordable medicines.

The move, announced at its New Kingston headquarters on July 10, intensifies competition in a region where Indian firms supply 40-50 per cent of generics, according to India’s High Commissioner to Jamaica, Shri Mayank Joshi. MSN executives cited Jamaica’s regulatory environment and logistics advantages as key factors in selecting it as a regional base, reflecting its stated long-term commitment while targeting over US$10 million in local sales.

MSN, one of India’s fastest-growing pharmaceutical firms, stated the subsidiary will leverage its research capabilities and manufacturing infrastructure to partner with local healthcare providers and policymakers. Initial focus will include chronic therapies for cardiovascular disease, diabetes, pain, and neurology, with plans to introduce oncology products subject to Jamaican regulatory approvals to reduce cancer treatment costs.

This expansion, extending MSN’s presence to over 100 countries, reinforces its commitment to ensuring timely supply of essential medicines and addressing healthcare access gaps.

“We are delighted to establish a direct presence in Jamaica,” Dr MSN Reddy, founder, chairman & managing director of MSN Group, said in a statement released with the launch of the local subsidiary. “This move aligns with our mission to deliver high-quality and affordable health-care solutions to people in every corner of the world. The Caribbean region holds great promise, and we are here to contribute meaningfully to its health-care advancement,” he continued.

Elaborating on the regional strategy, Vishal K Seth, MSN’s senior cluster head for Latin America and the English-speaking Caribbean, told the Jamaica Observer in an interview: “We see Jamaica as a future hub for the whole Caribbean. From Jamaica, we have already expanded to Trinidad and are entering Suriname, Barbados, Guyana, and The Bahamas,” he added, noting that “irrespective of market size, we want to improve access and get closer to patients.”

The strategy targets a Caribbean generics market where health inflation at 4.6 per cent in Jamaica over the last year has outpaced general price rises of 3.8 per cent. With only 22 per cent of Jamaicans having health insurance, Seth stated that MSN is “working closely with the Ministry of Health to provide solutions not present or regularly available”, particularly for oncology and rare diseases.

The company commits 10 per cent of global revenue, approximately US$140 million annually, to research and development. This enables production of complex generics at one-fifth to one-tenth of innovator costs, supporting portfolio expansion—over 60 oncology therapies and a dozen rare disease treatments — to deliver a compound annual growth rate (CAGR) of 30 to 40 per cent in the last three years.

Jayapala Reddy, senior vice-president (Emerging Markets), contrasted MSN’s model with “aggregator” distributors who dominate 80-90 per cent of the regional market: “Today, we have regulators, partners, and a team on the ground. That is where MSN differs.”

Currently, MSN’s generic drugs such as Atorvastatin — used in the management of cholesterol — and Breathezy, an MSN asthma medication supplied to Jamaica’s National Health Fund (NHF), hold 70-80 per cent market share in their respective categories, according to company executives. The subsidiary aims to add more NHF-listed products, including oncology launches, rare diseases, and orphan drugs — drugs used to treat rare diseases — to enable cost-free patient access.

Local distributors endorsed MSN’s model. Audley Williams, CEO of R A Williams Distributors Limited, cited an alignment on “affordable, quality pharmaceuticals”, while Lasco Group’s John De Silva spoke of a “shared commitment to health-care accessibility”.

Founded in 2003 and headquartered in Hyderabad, MSN Group operates 25 manufacturing facilities — 17 dedicated to active pharmaceutical ingredients and eight for finished dosage units — across India and the United States. It markets over 500 active ingredients and 400 formulations across 35 major therapeutic areas in 100+ countries. MSN holds more than 1,000 national and international patents and ranks as the world’s largest filer of active US Drug Master Files with more than 500 filings.

The investment serves to deepen India-Jamaica ties, with Joshi noting a pending memorandum of understanding on health-sector cooperation and Jamaica’s consideration of adopting the Indian Pharmacopoeia — a reference for drug formulas, purity standards, and quality control.

“This step concretises business relations and addresses health-care bottlenecks through shared innovation,” Joshi noted.

The establishment of MSN’s subsidiary underscores its strategy to leverage Jamaica’s location and regulatory framework as a base for expanding the supply of essential generic medicines throughout the Caribbean, aiming to improve access in markets facing significant health-care cost pressures.

From left: Indian High Commissioner to Jamaica Shri Mayank Joshi; Everton Anderson, CEO, National Health Fund; Jayapala Reddy, MSN’s senior vice-president (Emerging Markets); and Vishal K Seth, MSN’s senior cluster head for Latin America and the English-speaking Caribbean. (Naphtali Junior)

REDDY….Today, we have regulators, partners, and a team on the ground. That is where MSN differs. (Naphtali Junior)

Workers in one of MSN Laboratories’ facilities.